Optimizing Outcomes Across the Pharma Value Chain Network featuring Axendia
The ability of bio-pharmaceutical manufacturers to deliver quality drug products during challenging market conditions is critical for ensuring sustainability over the long run. The COVID-19 pandemic underscored the need to transform the traditional bio-pharmaceutical supply chain to have greater agility and resiliency during market swings and periods of volatility.
Listen to this on-demand webinar as Pharmaceutical Outsourcing Editor-in-Chief Mike Auerbach has a lively discussion with industry experts Daniel Matlis, President and Founder, Axendia, and David Leitham, SVP and GM, Pharmaceutical Business Unit, AspenTech, as they address these hot-button topics:
- What are the challenges that have limited the pharmaceutical industry from moving forward with digitalization?
- What is digital maturity and why is it a requirement for pharmaceutical manufacturing?
- Where should pharmaceutical companies begin their digitalization journey?
Learn more in this on-demand webinar.
Related Content
The COVID-19 pandemic highlighted the need for agility and resiliency within the supply chain for pharmaceutical companies. It is clear that speed to market will remain a top business imperative as we move into the next normal for pharma.